GLP-1 shortage or local stock problem? How to check availability

Direct answer: run a national check and a local check

Check the active ingredient in the live FDA Drug Shortage Database at the live FDA Drug Shortage Database for national regulatory status. Separately, ask the pharmacy that would dispense the prescription about the exact product and presentation. FDA status does not show a neighborhood pharmacy's shelf inventory, and one empty shelf does not prove a national shortage.

Date each check and label it precisely: ‘FDA national status checked 2026-07-23’ is different from a timestamped local-stock check. Keep both records even when collected on the same day because they answer different questions. Record an expected shipment as an estimate, not stock. Mark unclear answers unresolved and recheck. This guide cannot reserve a fill, forecast supply, or promise inventory when the prescription arrives.

What FDA national shortage status can and cannot tell you

FDA's live database is the starting point for national supply status. A current listing means FDA is aware of the situation, but the database is not an inventory feed for every pharmacy, warehouse, dose, or package. National status and a local fill are separate evidence: the latter depends on the exact transaction at a particular pharmacy.

The boundary works both ways. A nationally resolved shortage can coexist with a disruption at a city, chain, warehouse, or presentation; local stock does not determine FDA's national status. Use FDA for the national layer and the dispensing pharmacy for the local layer. This distinction prevents a regulatory label from becoming an unsupported shelf-stock claim. Neither source supports ‘available everywhere,’ ‘back nationwide,’ or ‘guaranteed to fill.’

The dated GLP-1 national-status snapshot

As of 2026-07-23, FDA said it determined the national semaglutide injection shortage resolved on 2025-02-21 and the national tirzepatide injection shortage resolved on 2024-12-19. These dated determinations do not claim stock at any pharmacy. FDA also notes intermittent localized supply disruptions, so ‘resolved’ nationally and ‘not available here’ can both be accurate.

Status can change after publication, so use the live database rather than this snapshot whenever current availability matters. FDA also says manufacturer-reported availability alone is not an FDA shortage-resolution determination. Keep ‘FDA national determination,’ ‘manufacturer report,’ and ‘pharmacy stock answer’ distinct; attach each statement to its source and check time. Recheck FDA and the responsible pharmacy when timing matters.

How to search the live FDA Drug Shortage Database

Open the FDA database and search the active ingredient, not only a brand nickname. Capture the result, exact status wording, date, and time. Keep separate entries or presentations separate. Search snippets, social posts, old news, and undated screenshots may aid discovery but cannot replace a fresh live-source check.

If the ingredient is missing, retry the spelling and review current and resolved results instead of declaring ‘no shortage.’ Record ‘database result not confirmed’ when appropriate; a failed result may reflect the query, browser state, or category rather than actual national status. Save the live URL, result view, and timestamp so another person can repeat the check without relying on your interpretation.

Identify the exact product and presentation before asking about stock

‘Do you have a GLP-1?’ is too broad. Use the exact product wording and presentation from the prescription or pharmacy record. Similar ingredient or brand references do not prove the same item can be dispensed. This is transaction identification, not treatment selection; do not ask staff to infer an item from an advertisement or this article.

Separate product identity from regulatory category. An FDA-approved branded drug, ingredient reference, and compounded preparation are not interchangeable labels. If an online offer uses only a familiar ingredient, ask what wording would appear on the prescription and dispensing label, which entity prepares the product, and which pharmacy fills it. Use the product-status guide for the accepted workflow. Unclear identity is a stop point, not evidence of equivalence.

Ask the dispensing pharmacy a transaction-specific set of questions

Follow the pharmacy's privacy process and ask whether the exact product and presentation is physically on hand for the intended fill, whether it can process the prescription now, and whether ‘available’ means on hand or orderable. If absent, ask about current backorder status or an expected window. Record the source, time, and qualifications without pressuring staff for a promise.

Ask what makes the answer final: must the pharmacy receive the prescription, is expected stock unallocated, and do network, price, or other commercial rules affect the transaction? Record whether confirmation expires or requires another call. These questions distinguish general inventory from a usable fill but guarantee neither. A price quote also does not reserve stock. Never publish an employee's estimate as a universal claim.

Treat expected shipments, waitlists, and transfers as provisional

‘Expected tomorrow’ does not mean ‘reserved.’ Shipments can change, differ in quantity, or be allocated first. Record dates as estimates and schedule a recheck. Define whether a waitlist is a notification list, ordering queue, or allocation process; do not treat a position as inventory ownership unless the pharmacy confirms the transaction.

A transfer is a process, not an inventory guarantee. Verify that the other location would dispense the exact product, accepts the transfer under its process, and can explain current stock. Reconfirm before relying on travel or timing. Keep treatment and prescribing outside this availability workflow. Direct product or prescription changes to a qualified healthcare professional; this article does not recommend switching brands, preparations, or presentations.

Expand the local search without turning it into an inventory promise

If one pharmacy lacks stock, build a bounded list of independently identified locations. Record each name, address, phone, check time, exact product, answer, next check, and unresolved price or network issue. A wider radius may reveal an option but does not prove processing; confirm the transaction before travel or payment.

Use consistent labels: on hand and confirmed; on hand but unconfirmed; orderable without a date; expected on a stated date; waitlist or notification only; unavailable; or no reliable answer. Preserve any qualification in the pharmacy's own wording. These worksheet categories are local operational labels, not FDA statuses, and should never be summarized as national findings. Retire stale rows because stock can change within a day.

Verify online alternatives instead of relaxing the evidence standard

Urgency should increase online verification. FDA says to check for a valid prescription requirement, U.S. and state licensure, pharmacist access, a physical address and phone, and privacy protections. Identify the dispensing pharmacy and verify it through the official state source; a logo, ‘partner pharmacy’ label, or shipping claim does not establish legal identity.

Use the pharmacy-verification guide and, for unclear product wording, the product-status guide. Itemize membership, provider services, medication, labs, supplies, shipping, and recurring terms using the total-cost guide. Confirm the pharmacy and product before paying or sending sensitive information. Online availability does not settle total cost, lawful dispensing, or local inventory. No staging-page link is an affiliate call to action.

Do not turn a shortage search into an FDA-approval assumption

A shortage or local stock problem does not change another product's regulatory status. FDA says compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness, or quality before marketing. Do not call a compounded preparation an FDA-approved replacement, generic equivalent, or the same product because it references semaglutide or tirzepatide. This guide makes no clinical comparison.

Before paying, identify the product, prescription process, compounder when relevant, and dispensing pharmacy. Preserve exact seller wording instead of translating an ingredient reference into a branded-product claim. FDA has warned about obscured sourcing and sameness claims in compounded GLP-1 marketing. A resolved date, out-of-stock notice, or delivery claim does not prove approval status. Verify product status separately and take medical questions to a qualified healthcare professional.

The GLP-1 availability verification checklist

Record the ingredient; exact product and presentation; live FDA result and timestamp; pharmacy identity, address, and phone; local timestamp; on-hand versus orderable wording; transaction confirmation; shipment estimate; next check; price or coverage questions; and unresolved conditions. Save the live URL and public pharmacy contact. Keep national findings in a separate field from local answers, and preserve each source's qualifications. Never enter ‘yes’ for a conditional answer.

Stop if product identity changes across the advertisement, prescription, or label; the dispensing pharmacy is unidentified or unverified; ‘available’ means only a future shipment; or pressure bypasses prescription, pharmacy, product-status, or total-cost checks. A stop point proves neither misconduct nor permanent unavailability; it means the intended transaction lacks sufficient evidence.

A decision framework for national and local results

Use four outcomes. National shortage plus unconfirmed local stock means document both and recheck without forecasting. National shortage plus a confirmed transaction means retain the confirmation but recognize inventory can change. Resolved national status plus unconfirmed stock is a local problem, not a revised FDA status. If both checks are clear, ordinary price, pharmacy, prescription, and timing conditions still apply.

Collect evidence rather than recommend treatment. Identify the missing fact, its owner, and its expiry. FDA owns national shortage status; the pharmacy owns stock and processing; the seller or program owns commercial terms; a qualified healthcare professional handles individual medical questions. If two answers appear inconsistent, compare their dates, products, presentations, locations, and evidence layers before calling either wrong. Do not stretch one source's answer beyond that scope.

Common failure modes and how to correct them

Do not treat resolved national status as local stock; ask the pharmacy. Do not treat one empty pharmacy as a national shortage; check FDA. Replace old articles, snippets, or screenshots with a dated live-source capture. When told ‘available,’ preserve whether that means on hand, orderable, expected, or reserved.

Urgency does not excuse verification. Do not infer a brand from an ingredient headline, assume a compound is FDA-approved, accept an unidentified pharmacy, compare medication-only price with a program total, treat estimates as promises, or travel without reconfirming. A confident seller statement does not replace FDA or pharmacy evidence. Identify the object, ask its authoritative source, date the answer, preserve qualifications, and show unknowns.

Keep a dated availability record that another person can audit

Separate copied language from interpretation. Save the FDA URL, search term, result, and timestamp. For each pharmacy, record location, public contact, exact item, on-hand or orderable wording, transaction status, estimate, next check, and a no-guarantee note. For an online program, preserve the product page, pharmacy identity, itemized quote, recurring terms, and clarifying responses.

Keep sensitive health and payment details out of informal shared worksheets. Retain only enough transaction context to repeat the check, using the pharmacy's privacy process for personal information. Review the record immediately before acting because local answers expire quickly. Append new dated entries instead of overwriting old ones so changes remain attributable to FDA status, pharmacy stock, seller terms, or timing. An audit trail documents change; it does not guarantee a fill.

Frequently asked questions

Are Wegovy and Zepbound in shortage? As of 2026-07-23, FDA said the national semaglutide injection shortage was resolved on 2025-02-21 and the national tirzepatide injection shortage on 2024-12-19. These are not permanent or local-stock claims; check the live database and pharmacy. FDA notes localized disruptions may still occur.

Does manufacturer ‘available’ settle FDA status? No; FDA says it is not itself a resolution determination. Does resolved guarantee every presentation? No. Is expected delivery reserved? Only if the responsible pharmacy confirms that transaction under its process. Does shortage status make a compound FDA-approved or equivalent? No; compounded drugs are not FDA-approved, and no equivalence is implied. Can this guide choose an alternative? No; it provides verification, not treatment or prescribing advice.

Sources and related accepted guides

Primary sources checked through 2026-07-23 were FDA's Drug Shortages page, updated 2026-07-15; the live FDA Drug Shortage Database; FDA's April 1, 2026 GLP-1 supply policy update; FDA's June 15, 2026 concerns page; and FDA online-pharmacy guidance. Exact links appear in the source list below.

Related accepted pages: the product-status guide, the pharmacy-verification guide, the total-cost guide, and the online-program cost comparison. Use them for product-status, pharmacy, and cost verification without treating one workflow as proof for another. These links are educational and non-promotional in this educational batch. They do not activate an affiliate offer, promise local inventory, authorize indexing, establish clinician authority, or release this page for deployment.

Sources

1. U.S. Food and Drug Administration · supports shortage-database-first · checked 2026-07-23
2. U.S. Food and Drug Administration · supports shortage-database-first · checked 2026-07-23
3. U.S. Food and Drug Administration · supports national-status-not-local-stock, semaglutide-national-resolution, tirzepatide-national-resolution, manufacturer-availability-boundary · checked 2026-07-23
4. U.S. Food and Drug Administration · supports compounded-product-status · checked 2026-07-23
5. U.S. Food and Drug Administration · supports online-pharmacy-verification · checked 2026-07-23

Next step

Use the live FDA Drug Shortage Database for national status, then check the responsible pharmacy for the exact prescribed product and presentation. Date each result, preserve qualifications, and treat shipments, transfers, and online offers as unconfirmed until the pharmacy verifies the transaction. No listing, update, estimate, or article guarantees inventory.